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4%. Four lambs received the ]Iz receptor antagonist, metiamide, and the mean R'APVR due to tolazoline was -18 + 5%. After both I l l and [I2 antagonists, the mean %APVR due to tolazoline was +6 + 8%. Therefore, both histamine 11, and 112 receptors were involved in the vasodilator response to tolazoline.
Speculation
If the puln~onary vasodilator action of tolazoline is n~ediated by histamine receptors in human infants, as it is in newborn lambs, it may be possible to select a more specific therapeutic agent for infants with pulmonary vasospasm. liistamine, 2-methylhistamine, a specific I i l agonist, or 4-methylhistamine, a specific 112 agonist, may be such agents in certain situations.
Tolazoline hydrochloride has been reported to reduce the elevated pulmonary vascular resistance seen in primary pulmonary hypertension (7, 8) , mitral stenosis (5), congenital heart disease (4, I I), cystic fibrosis (12) . respiratory distress syndrome of the newborn (6) , and "persistence of the fetal circulation" (10, 13) .
Tolazoline is classified pharmacologically as an a-adrenergic blocking agent. In addition, it has direct actions on cardiac and smooth muscle which are described as sympathomimetic. parasympathomimetic, and "histamine-like" (15) . Dual histamine receptors, called H I and Ha receptors, have recently been described (3) . Tolazoline has been shown to interact with histamine H2 receptors in gastric mucosa and cardiac atria to produce its histamine-like effect (16, 19) . however, the blood vessels of the lung have not been studied in this regard. In the pulmonary circulation of adult animals, histamine H I receptors mediate vasoconstriction and Hz receptors mediate vasodilatation (IS), whereas in the fetus both receptors may mediate pulmonary vasodilatation (18).
The pirpose o f the present study was to demonstrate that the pulmonary vasodilator action of tolazoline is mediated via histamine receptors.
EXPERIMENTAL METHOD
Newborn lambs, 0-to 3-days-old, weighing 3.1-5.4 kg, were anesthetized with a a-chloralose, tracheotomized, and ventilated with a Harvard small animal ventilator. Cannulae were placed in the aorta and inferior vena cava from a femoral approach. The heart and great vessels were exposed through a left lateral thoracotomy and the ductus arteriosus was ligated. Cannulae were inserted into the left atrium and pulmonary artery. All cannulae were connected to pressure transducers and appropriate electronic amplifiers. The following were recorded on a strip chart recorder: Mean pulmonary blood flow, Q,,; mean pulmonary artery pressure, 9 and airway pressure wa_s monitored and end expiratory pre_ssure was maintained below PI.A PVR was calculated as (PPA -PI.A)/ Q,,. The units of pressure measurement were mm Hg and the flow measurements were measured as ml/min and then standardized per kg of body, ml/min/kg, for the resistance calculations.
Intermittent arterial blood gas analysis was performed to assess acid-base and oxygenation status. Rectal temperature was maintained at 38.540°C.
Pharmacologic agents were administered in boluses via the inferior vena cava cannula in the following doses: tolazoline (Priscoline, CIBA Pharmaceuticals, Summit, NJ), I mg/kg; diphenhydramine (HI receptor antagonist) 5 mg/kg; and metiamide (kindly supplied by John G. Paul of Smith, Kline, and French Laboratories, Philadelphia, PA) (Hz receptor antagonist), 5 mg/ kg. Initially, the effect of tolazoline, 1 mg/kg, on PVR was determined before the administration of antagonists in all eight lambs. In lambs 1 4 , the effect of tolazoline on PVR was then evaluated after H I receptor blockade with diphenhydramine and in lambs 5-8 the effect of tolazoline was evaluated after Hz receptor blockade with metiamide. Finally, the effect of tolazoline on PVR was evaluated in all eight lambs after both H I and H2 receptor blockade.
In lambs 3-7, before administration of any histamine antagonists, the PVR was elevated by ventilating the lambs with an 8-10% oxygen mixture balanced with nitrogen. The effect of tolazoline on the increased PVR due to alveolar hypoxia was then evaluated.
In four additional lambs, tachyphylaxis to tolazoline was evaluated by the administration of four consecutive 1 mg/kg doses of tolazoline at 10-min intervals with the determination of fall in PVR after each dose. No histamine antagonists were used in these animals.
For purposes of analysis, maximal changes in PVR after tolazoline administration, APVR, were calculated as percents of the base line value, %APVR. Means of %APVR, before and after histamine receptor antagonists, were then compared using the Student's t test.
RESULTS
The mean f SD base line values for the eight lambq studied were = 37.9 -t 8.6 mm HE, P1.A = 4.5 f 2.5 mm HE. Q p = 287 f 60 ml/kg/min, and PVR-= 0.1 1 + 0.4 mm ~~/ u m l ; k~/ m i n (Table 1) . After 'the administration of tolazoline, 1 mg/kg, the mean %APVR f SD for all eight lambs was -25 -t 4%. In lambs 1 4 , in the presence of the H I receptor antagonist, diphenhydramine, the mean %APVR f SD produced by tolazoline was -12 f 4%. In lambs 5-8, in the presence of the Ha receptor antagonist, metiamide, the mean %APVR f SD produced by tolazoline was -18 f 6%. The mean %APVR + SD produced by tolazoline after administration of both H I and Hz antagonists to all eight lambs was +6 +-8% ( Table 2 ). The mean %APVR's due to tolazoline after the administration of each single histamine antagonist as well as the combined H I and H2 antagonists were significantly different from the mean %APVR produced by tolazoline alone (P < 0.01). Lambs Table 2) .
The duration of action of tolazoline on the pulmonary circulation varied from 40-210 sec with a mean of 122 sec.
Lambs 3-7 were ventilated with 8-10% Oz (resultant arterial PaOz (17-29 torr) and the PVR rose from a mean of 0.133 + 0.044 to 0.186 f 0.052 mm Hg/ml/kg/min (Table 3 ). The administration of tolazoline, 1 mg/kg, lowered the mean PVR to 0.139 k 0.049 mm Hg/ml/kg/min, not statistically different from the base line mean PVR before alveolar hypoxia. The duration of action of tolazoline during alveolar hypoxia was similar to that for the nonhypoxic state. ' Statistically different from mean in column I at P < 0.005. ' Significantly different from means in first and third columns at P < 0.05.
In the four additional lambs receiving four consecutive doses of tolazoline, 1 mg/kg, at 10-min intervals, no tachyphylaxis in the PVR response to tolazoline was observed. The fall in PVR consistently slightly increased with consecutive doses of tolazoline, with the means of %APVR of -21% on the fourth dose being similar to the initial %APVR of -26% for lambs 1-8.
DISCUSSION
These results demonstrate that the pulmonary vasodilator effect of tolazoline in the newborn lamb is mediated by both histamine H I and Hp receptors. Work in our laboratory (unpublished) with histamine and specific H I and Hy receptor antagonists has demonstrated that both H I and Hy receptors mediate pulmonary vasodilatation in newborn lambs, 0-to 3-days-old. This finding is compatible with those of Woods et al. (18) that both HI and H:! receptors mediate pulmonary vasodilatation in the sheep fetus. However, H I receptors appear to mediate pulmonary vasoconstriction and Hz receptors to mediate pulmonary vasodilatation in adult dogs (17) . Thus, tolazoline may not be an effective pulmonary vasodilator in the older animals.
The increase in PVR produced by tolazoline after histamine HI and H2 receptor blockade in this study may be due to the unmasking of an adrenergic vasoconstrictor action. Benfey and Varma (2) have previously demonstrated such an adrenergic vasoconstrictor action of tolazoline in the peripheral circulation of cats treated with reserpine. It should be noted that, unlike tolazoline, histamine, 0.5-1.0 pg/kg, continues to have a pulmonary vasodilator effect after administration of both H I and Hz blocking agents. A non-HI-Hz receptor effect has been postulated at these large histamine doses (9) .
Our findings, that the pulmonary vasodilator action of tolazoline is due to its histamine-like effect and not its cx-adrenergic blocking effect are in agreement with the findings of MacKinnon et al. (14) that another adrenergic blocking agent, hydergine. when injected directly into the pulmonary artery had no significant effect on pulmonary hemodynamics regardless of the initial level of total PVR.
The duration of the vasodilator action of tolazoline after administration as a bolus dose was short, mean 122 sec, and similar to the duration of action of histamine, 0.05 &kg, administered to newborn lambs in our laboratory. In preliminary studies in our laboratory (unpublished), continuous infusion of tolazoline at rates of 6-10 mg/kg/hr has been required before obtaining any effect on pulmonary vascular resistance. This raises a question about the use of continuous infusions of tolazoline in human infants with pulmonary vasospasm (10) . Further study is necessary to demonstrate whether continuous infusion or bolus administration is more effective in humans.
The effectiveness of the bolus adminstration of tolazoline, with its short duraton of action in reversing pulmonary vasospasm in human infants (10, 13) suggests that a reflex mechar?ism for maintaining high PVR once it is established may be present in the newborn and probably in the fetus. We have observed one lamb (#5) that maintained a high PVR after the change of ventilatory gas from 8% Oq to room air. The P a 0 2 was 26 torr while receiving 8% O 2 and rose only to 29 torr after 5-8 min of ventilation with room air. Because the ductus arteriosus had been ligated, it was presumed that a large atrial right-to-left shunt was responsible for the continued hypoxemia. After the administration of tolazoline (I mg/kg), the PVR fell to the base line level (Table 3 ) and the PaOz immediately rose to 69 torr. We were able to reproduce this set of circumstances in this lamb, but not in its twin.
Because tolazoline has so many different pharmacologic actions, it must be used with care therapeutically. If the pulmonary vasodilator action of tolazoline in humans is due solely to its histaminelike activity, as in the lamb, then it may be reasonable to select a histamine or histamine derivative for use as a pulmonary vasodilator agent in newborn infants with pulmonary vasospasm. The pure H I receptor agonist, 2-methylhistamine, might be a good choice because it would minimize the gastric and cardiac effects of histamine mediated by histamine H z receptors (1). However, in older infants, the H I receptor may mediate pulmonary vasoconstriction and an H P receptor agonist may be more appropriate. Another advantage of histamine is its rapid destruction by histaminases present in the blood. Little emphasis should be necessary that these hypotheses require rigorous testing.
CONCLUSION
Tolazoline was found to produce pulmonary vasodilatation in newborn lambs with normal PVR as well as when PVR was elevated by alveolar hypoxia. This vasodilator action of tolazoline was shown to be mediated via histamine receptors. Both histamine H I and Hz receptors were involved in the vasodilator response.
